Cogent Biosciences third quarter 2026 loss widens to $111.4M ahead of November PDUFA date

Cogent Biosciences reported a net loss of $111.4 million for the third quarter 2026 and generated no revenue, consistent with its pre-commercial stage. The company is aggressively scaling its general and administrative infrastructure, which saw expenses nearly triple year-over-year, in preparation for the anticipated commercial launch of bezuclastinib following its first FDA action date later this month.

Key Highlights

• General and administrative expenses surged to $42.1 million from $14.4 million in the prior year, driven by the build-out of commercial personnel and infrastructure.
• The company maintains a robust cash, cash equivalents, and marketable securities balance of $791.1 million, providing an estimated operational runway into late 2028.
• Bezuclastinib faces three major regulatory catalysts with PDUFA dates set for November 30, 2026 (GIST), December 30, 2026 (NonAdvSM), and June 29, 2027 (AdvSM).